ライフサイエンスコーパス: ESRD

1 ESRD is considered a central outcome, and a method for e

2 ESRD occurred in 56% of patients, and 26% of patients di

3 ESRD was determined as the need for chronic dialysis or

4 ESRD was the outcome of interest.

5 median follow-up of 5 years, we observed 70 ESRD events and 48 deaths.

6 ncentration, and CKD stage at onset affected ESRD risk.

7 reased significantly for LT recipients after ESRD onset.

8 , progressed to ESRD before 10 years of age, ESRD occurred almost exclusively in the second decade of

9 With an aging ESRD population and continued organ shortage, preservati

10 ine, and related adverse health events (AKI, ESRD, hypertension, diabetes, cardiovascular disease, pr

11 Although ESRD disproportionately affects racial/ethnic minorities

12 Among ESRD patients age >/=60 years, receipt of HZ vaccine was

13 vaccination and the subsequent HZ risk among ESRD patients.

14 s of renal failure progression (P=0.002) and ESRD (P=0.01) during follow-up.

15 m(2), incident CKD, eGFR decline >/=30%, and ESRD over a median follow-up of 8.52 years.

16 per 1.73 m(2), CKD, eGFR decline >/=30%, and ESRD.

17 >/=30% (HR, 1.28; 95% CI, 1.18 to 1.39), and ESRD (HR, 1.26; 95% CI, 1.17 to 1.35).

18 Patients with CKD and ESRD have increased in-hospital mortality and periproced

19 , but their association with risk of CKD and ESRD is unknown.

20 Diabetes is the main cause of CKD and ESRD worldwide.

21 Pre-existing CKD and ESRD, and postoperative AKI were the main independent pr

22 y disease, a condition that leads to CKD and ESRD.

23 h no CKD, CKD with no AKI, AKI with CKD, and ESRD, respectively (P < 0.001).

24 and risk of incident CKD, eGFR decline, and ESRD.

25 higher risk for hypertension, diabetes, and ESRD only.

26 ication that leads to kidney dysfunction and ESRD, but the underlying mechanisms remain unclear.

27 In conclusion, severe reduction in GFR and ESRD after kidney donation were uncommon and were highly

28 ed the risk of proteinuria, reduced GFR, and ESRD in 3956 white kidney donors, assessed the contribut

29 o developed tubulointerstitial nephritis and ESRD in association with autoantibodies against kidney c

30 ny other tissues, with systemic oxalosis and ESRD being a common outcome.

31 d risk of incident CKD, CKD progression, and ESRD.

32 nt coronary heart disease (CHD), stroke, and ESRD was examined using Cox models adjusted for sociodem

33 d with all-cause mortality, CHD, stroke, and ESRD were incrementally higher.

34 sks of all-cause mortality, CHD, stroke, and ESRD.

35 ociation between these hemoglobin traits and ESRD remains unknown.

36 e changes and acceptable end points, such as ESRD, has limited its utility.

37 an Americans with type 2 diabetes-associated ESRD, and 1029 non-nephropathy controls.

38 iabetic ESRD, P=0.57 for diabetes-associated ESRD, and P=0.27 for all-cause ESRD).

39 at were significantly associated with age at ESRD onset, and a scoring system from 0 to 9 was develop

40 e the association between body mass index at ESRD onset and survival and transplantation in children,

41 f ESRD-free patients to each LT recipient at ESRD onset.

42 ted nephropathy, and hypertension-attributed ESRD among people of recent African ancestry.

43 ncrease in the risk of ESRD and death before ESRD in patients with CKD.

44 antation could enhance communication between ESRD patients and their clinicians when making decisions

45 es-associated ESRD, and P=0.27 for all-cause ESRD).

46 t common primary glomerular disorder causing ESRD, is a complex disease that is only partially unders

47 ociation with the compounding issues of CKD, ESRD, and kidney transplantation.

48 CKD or ESRD with those patients with no CKD/ESRD.

49 ing one such pilot project-the Comprehensive ESRD Care (CEC) initiative-to include patients with adva

50 Conversely, ESRD-related cancer incidence was lower during kidney fu

51 a composite of doubling of serum creatinine, ESRD, or death between 100 Rtx-treated patients and 103

52 nephropathy, resulting in similar cumulative ESRD rates (>85% for each disorder) in the third decade

53 n per 1.73 m(2) or ESRD (28 donors developed ESRD).

54 of 15 (26%) positive patients had developed ESRD or died.

55 Our patient developed ESRD and early recurrence after transplantation.

56 r finding that 39 of 99 donors who developed ESRD never listed for a transplant warrants further stud

57 n April 1994 and November 2011 who developed ESRD, 78 initially received dialysis (of whom 37 listed

58 1 tended to have a higher risk of developing ESRD (HR, 3.60 95% CI 1.83-7.07) compared with nonchroni

59 ociated with an increased risk of developing ESRD and suggests that elevated serum levels of HCV RNA

60 l and genotype affect the risk of developing ESRD.

61 the progression to end-stage renal disease (ESRD) after discharge.

62 donors can develop end-stage renal disease (ESRD) after donation, but the outcomes of those who do r

63 ciation of incident end-stage renal disease (ESRD) after liver transplantation (LT) and resource util

64 ver (FMF) who reach end-stage renal disease (ESRD) due to reactive amyloidosis A (AA) are scarce and

65 m 1,5-AG levels and end-stage renal disease (ESRD) from baseline (1990-1992) through 2013 with adjust

66 apid progression to end-stage renal disease (ESRD) in a cohort of proteinuric patients with type 1 di

67 ascular events, and end-stage renal disease (ESRD) in a large cohort of U.S. veterans.

68 nearly one third of end-stage renal disease (ESRD) patients are not educated about kidney transplanta

69 disease (ESLD) and end-stage renal disease (ESRD) patients awaiting transplant.

70 ter (HZ) vaccine in end-stage renal disease (ESRD) patients might be insufficient, considering data d

71 (HCV) infection and end-stage renal disease (ESRD) remains controversial without considering the role

72 = 0.06) and time to end stage renal disease (ESRD) was longer in this group (P = 0.03).

73 pecially those with end-stage renal disease (ESRD), are controversial.

74 important cause of end-stage renal disease (ESRD), which requires transplantation or dialysis.

75 with development of end-stage renal disease (ESRD).

76 k of progression to end-stage renal disease (ESRD).

77 ected patients with end-stage renal disease (ESRD).

78 ey disease (CKD) to end-stage renal disease (ESRD).

79 ogression to CKD or end-stage renal disease (ESRD).

80 al risk factors for end-stage renal disease (ESRD).

81 of patients develop end-stage renal disease (ESRD).

82 ascular outcome-and end-stage renal disease [ESRD], doubling of serum creatinine, and all-cause morta

83 on, 4% and 8% of the cohort had pre-existing ESRD and CKD not requiring renal replacement therapy, re

84 l, 5.00-6.49) for patients with pre-existing ESRD.

85 pectoris, hospitalization for heart failure, ESRD, or doubling serum creatinine.

86 Aggressive pain treatment was advocated for ESRD patients, but new Centers for Disease Control and P

87 to ESRD, with corresponding median ages for ESRD onset of 70.6, 56.9, and 49 years, respectively.

88 isease etiology, improve risk assessment for ESRD, and pave the way for personalized treatment.

89 king pre-ESRD death as a competing event for ESRD.

90 CKD is a major risk factor for ESRD, cardiovascular disease, and premature death.

91 We assessed risk factors for ESRD using multivariate Cox regression models.

92 used to determine the hazard ratio (HR) for ESRD.

93 mate subdistribution hazard ratios (HRs) for ESRD.

94 inform the ability of surrogate outcomes for ESRD to predict the efficacy of various interventions on

95 after AKI could be a surrogate end point for ESRD in trials of AKI prevention and/or treatment, but a

96 The incidence rate for ESRD among participants with APOL1 high-risk genotypes w

97 The incidence rate for ESRD was 8.5 per 1000 person-years for participants with

98 er quartiles combined had a hazard ratio for ESRD of 1.24 (95% confidence interval [95% CI], 1.05 to

99 r 1000 person-years, with a hazard ratio for ESRD of 1.77 (95% confidence interval, 1.31 to 2.38) for

100 individuals with SCT had a hazard ratio for ESRD of 2.03 (95% confidence interval, 1.44 to 2.84).

101 d mesangial expansion and decreased risk for ESRD (subdistribution HR, 0.64; 95% confidence interval,

102 ESRD in blacks, and this degree of risk for ESRD was similar to that conferred by APOL1 high-risk ge

103 dictive value of 81.4%, a score >6 forecasts ESRD onset before 60 years of age with a positive predic

104 ss to kidney transplantation (KT), time from ESRD to listing, time from listing to KT, and post-KT gr

105 ocial Security Death Index; 397 patients had ESRD and 475 deaths occurred during a median follow-up o

106 n efforts targeting patients who are at high ESRD risk may reduce post-LT ESRD incidence and hence de

107 food frequency questionnaire and identified ESRD via record linkage with a nationwide registry.

108 days hospitalized patient per year was 23 in ESRD and 7 in non-ESRD LT recipients.

109 r mortality is the leading cause of death in ESRD.

110 In conclusion, chronic exposure to FO in ESRD is a strong risk factor for death across discrete B

111 weight gain and intradialytic hypotension in ESRD.

112 trajectory does not explain any increase in ESRD after donation.

113 tibodies (PRAs), are related to mortality in ESRD.

114 ause premature arterial aging is observed in ESRD, we determined the respective roles of stiffness an

115 a novel intervention to improve olfaction in ESRD.

116 stic kidney disease (ADPKD) often results in ESRD but with a highly variable course.

117 Incident ESRD occurred in 40 of 739 (5.4%) individuals with SCT,

118 fidence interval, 0.39 to 0.95) and incident ESRD (hazard ratio, 0.50; 95% confidence interval, 0.30

119 ine PIIINP with CKD progression and incident ESRD.

120 and CKD progression was defined as incident ESRD or halving of eGFR.

121 r 25-ml/min per 1.73 m(2) decline), incident ESRD, death, or composite outcomes.

122 n (50% eGFR loss or incident ESRD), incident ESRD, and all-cause mortality, and linear mixed-effects

123 ficantly in event-free survival for incident ESRD and composite outcomes (P</=0.001 by log-rank test)

124 ratios for the composite outcome of incident ESRD and change in GFR: GSTM1 active/APOL1 high-risk haz

125 are associated with higher risk of incident ESRD independent of baseline kidney function but not ind

126 We used a national cohort of incident ESRD patients in the US Renal Data System surveillance r

127 , CKD progression (50% eGFR loss or incident ESRD), incident ESRD, and all-cause mortality, and linea

128 ly higher rates of CKD progression, incident ESRD, and mean annual decline in eGFR than did NHW (P<0.

129 had CKD progression, 21.3% reached incident ESRD, and 18.3% died.

130 Primary outcomes were incident ESRD, eGFR slope, log-transformed UPCR slope, and all-ca

131 sociations of both metabolites with incident ESRD disappeared upon adjustment for measured GFR.

132 h mortality in 39,566 patients with incident ESRD in a large dialysis network in 26 countries using w

133 This cohort study included ESRD patients age >/=60 years who were enrolled in Kaise

134 Studies of lipids in CKD, including ESRD, have been limited to measures of conventional lipi

135 leep fragmentation associated with increased ESRD risk (hazard ratio, 1.04; 95% confidence interval,

136 Evidence suggests that for HIV-infected ESRD patients, KT is associated with a significant survi

137 ty-affiliated hemodialysis centers involving ESRD patients with poor attendance, defined as missing 2

138 who are at high ESRD risk may reduce post-LT ESRD incidence and hence decrease morbidity and cost amo

139 patient per year was 23 in ESRD and 7 in non-ESRD LT recipients.

140 % higher after reaching ESRD compared to non-ESRD (hazard ratio, 1.97; P < 0.0001).

141 associated with ESRD (P=0.05 for nondiabetic ESRD, P=0.57 for diabetes-associated ESRD, and P=0.27 fo

142 ed in 937 African Americans with nondiabetic ESRD, 965 African Americans with type 2 diabetes-associa

143 CAKUT causes approximately 40% of ESRD that manifests within the first three decades of li

144 30% (HR, 1.32; 95% CI, 1.28 to 1.37), and of ESRD (HR, 1.96; 95% CI, 1.21 to 3.18).

145 The association of ESRD and post-LT hospitalization was assessed by sequent

146 decade, it is unknown whether the burden of ESRD due to multiple myeloma has changed, or whether sur

147 In all, 951 cases of ESRD occurred over a mean follow-up of 15.5 years.

148 ney disease (ADPKD) is an important cause of ESRD for which there exists no approved therapy in the U

149 erential outcomes by GN subtype and cause of ESRD should be examined in future research.

150 tic nephropathy (DN) is the leading cause of ESRD worldwide.

151 ney diseases (ADPKD), a significant cause of ESRD, and autosomal dominant polycystic liver diseases (

152 Diabetes is the leading cause of ESRD.

153 older age, shorter height, family history of ESRD, higher serum uric acid level, and lower measured G

154 project the estimated long-term incidence of ESRD among persons who do not donate a kidney, according

155 ibrated to the population-level incidence of ESRD and mortality in the United States, to project the

156 urces of protein may reduce the incidence of ESRD.

157 hazard ratios (95% confidence intervals) of ESRD of 5.60 (4.06 to 7.71), 6.42 (4.76 to 8.65), and 7.

158 which entailed prognostic score matching of ESRD-free patients to each LT recipient at ESRD onset.

159 the transplant occurred within 18 months of ESRD onset.

160 trict BP control does not delay the onset of ESRD but may reduce the relative risk of death in CKD.

161 and HCV genotype 1 are strong predictors of ESRD, indicating clinical implications for the managemen

162 on renal biopsy as independent predictors of ESRD.

163 The incidence rates of ESRD for nonchronically HCV-infected and chronically HCV

164 blacks continue to have much higher rates of ESRD than HIV-positive whites, which could be attributed

165 Demography-adjusted incidence ratios of ESRD from multiple myeloma decreased between 2001-2002 a

166 Previous studies reported the risk of ESRD after kidney donation, but not the renal outcomes t

167 to estimate the projected long-term risk of ESRD among living kidney-donor candidates and to inform

168 1.44 to 1.66; P<0.001) times higher risk of ESRD and 1.23 (95% confidence interval, 1.12 to 1.34; P<

169 ated with a stepwise increase in the risk of ESRD and death before ESRD in patients with CKD.

170 Here, we determined the risk of ESRD and mortality during extended follow-up of the Afri

171 BP lowering and its association with risk of ESRD are unclear.

172 tion processes has identified higher risk of ESRD attributable to donation in two studies; importantl

173 Predicted 20-year risk of ESRD for the median donor was only 34 cases per 10,000 d

174 An increased risk of ESRD has been reported for living kidney donors, and app

175 timate a person's probable long-term risk of ESRD if that person does not donate a kidney.

176 genotype associated only with higher risk of ESRD in a fully adjusted analysis.

177 ependently associated with increased risk of ESRD in a nationally representative population.

178 usual BP arm associated with higher risk of ESRD in AASK (aHR, 1.83; 95% CI, 1.30 to 2.57) and MDRD

179 eGFR decline associated with higher risk of ESRD in both strict and usual BP arms.

180 nd a method for estimating long-term risk of ESRD in donor candidates is described.

181 P<0.001) was associated with higher risk of ESRD in donors.

182 ring did not associate with a higher risk of ESRD in the AASK (adjusted hazard ratio [aHR], 1.19; 95%

183 nors, the 15-year projections of the risk of ESRD in the absence of donation varied according to race

184 hat red meat intake may increase the risk of ESRD in the general population and substituting alternat

185 od sources of dietary protein on the risk of ESRD in the general population remain unclear.

186 d high HCV RNA levels were at higher risk of ESRD than those who were nonchronically HCV-infected (HR

187 the AASK trials, unadjusted relative risk of ESRD was 0.88 (95% CI, 0.78 to 1.00) and unadjusted rela

188 odel-based lifetime projections, the risk of ESRD was highest among persons in the youngest age group

189 ently show enhanced association with risk of ESRD, cardiovascular events, or death.

190 trials in CKD associated with higher risk of ESRD, we performed a retrospective study of 899 African

191 airy products did not associate with risk of ESRD.

192 of proteinuria and a >2-fold higher risk of ESRD.

193 ad unadjusted and adjusted relative risks of ESRD of 0.92 (95% confidence interval [95% CI], 0.75 to

194 of kidney function over 2 years and risks of ESRD, nonfatal cardiovascular events, and all-cause mort

195 ntation as a treatment option at the time of ESRD diagnosis.

196 w used widely for the long-term treatment of ESRD, have significantly reduced therapy-related complic

197 rrogate end points for a treatment effect on ESRD in patients with primary MN with heavy proteinuria.

198 ict the efficacy of various interventions on ESRD.

199 ad either an eGFR<30 ml/min per 1.73 m(2) or ESRD (28 donors developed ESRD).

200 An eGFR<30 ml/min per 1.73 m(2) or ESRD associated with older age (HR, 1.07; 95% CI, 1.05 t

201 of >/=50% decrease in eGFR from baseline or ESRD, occurred in 15 intensive group and 16 standard gro

202 Patients with CKD or ESRD had greater in-hospital mortality, hospital length

203 in-hospital outcomes of patients with CKD or ESRD with those patients with no CKD/ESRD.

204 for suitable candidates with advanced CKD or ESRD.

205 and glomerular scarring can result in CKD or ESRD.

206 rait did not associate with prevalent CKD or ESRD.

207 iates with incident CKD, CKD progression, or ESRD is not known.

208 crease in age-standardized mortality risk or ESRD.

209 e estimated the average risk of postdonation ESRD for living kidney donors in the United States, but

210 nsion, diabetes, cardiovascular disease, pre-ESRD and total hospitalization rate, and mortality).

211 association remained robust after taking pre-ESRD death as a competing event for ESRD.

212 ion, but not the renal outcomes that precede ESRD.

213 ed the proportion of patients with prevalent ESRD in each facility referred for transplant within 1 y

214 g nephrogenic diabetes insipidus and rarely, ESRD.

215 1.73 m(2)with 9% of patients having reached ESRD; 59% and 50% of patients achieved complete clinical

216 alization rate was 97% higher after reaching ESRD compared to non-ESRD (hazard ratio, 1.97; P < 0.000

217 ts, and 26% of patients died before reaching ESRD.

218 The proportion of patients reaching ESRD or a 50% reduction of renal function was significan

219 varies among individuals, with some reaching ESRD before 40 years of age and others never requiring R

220 Regarding ESRD due to multiple myeloma necessitating RRT in the Un

221 iciently strong relationship with subsequent ESRD to serve as an alternative end point in trials of A

222 One possibility is that ESRD is due to the nephrectomy-related reduction in GFR,

223 The ESRD Prospective Payment System associated with a 5.0% (

224 The ESRD Prospective Payment System bundling, but not the tr

225 The ESRD Prospective Payment System introduced two incentive

226 The ESRD Quality Incentive Program (QIP) is the first mandat

227 We evaluated the effects of the ESRD Prospective Payment System on home dialysis use by

228 ssment and quality measures, focusing on the ESRD QIP, its effect on care, and its potential future d

229 The QIP is tied to the ESRD prospective payment system and mandated by the Medi

230 dress the transition of patients from CKD to ESRD, a particularly vulnerable time for patients.

231 advantage in cumulative survival compared to ESRD patients without KT (P = 0.07).

232 or prognostic indicators of time from DKD to ESRD.

233 Whereas a score </=3 eliminates evolution to ESRD before 60 years of age with a negative predictive v

234 mission of the disease process that leads to ESRD.

235 isk genotype were more likely to progress to ESRD (P<0.01).

236 of renal pathologies that often progress to ESRD, but the molecular mechanisms underlying this progr

237 ter excluding 916 patients who progressed to ESRD after discharge, although it was significantly ampl

238 with THSD7A-associated MN who progressed to ESRD and subsequently underwent renal transplantation.

239 n WT1 and NPHS2, respectively, progressed to ESRD before 10 years of age, ESRD occurred almost exclus

240 iable option for many who have progressed to ESRD.

241 that, in most patients, slowly progresses to ESRD.

242 vy proteinuria that eventually progresses to ESRD.

243 opulation at highest risk for progressing to ESRD.

244 diabetic kidney disease (DKD) progression to ESRD are lacking.

245 ongly associated with risk of progression to ESRD in blacks, and this degree of risk for ESRD was sim

246 int of 30% decline in eGFR or progression to ESRD over a median of 1.8 and 2.0 years of follow up, re

247 still common and the rate of progression to ESRD remained unacceptably high.

248 r OLT, but the association of progression to ESRD was particularly high among patients with both diab

249 n, severe arrhythmia, stroke, progression to ESRD), changes in cardiac and renal function, Fabry-rela

250 and high risk (7-9 points) of progression to ESRD, with corresponding median ages for ESRD onset of 7

251 s nephropathy at high risk of progression to ESRD.

252 ong the highest risks for CKD progression to ESRD.

253 ue of histologic findings in DKD for time to ESRD in native kidney specimens from biopsies performed

254 for association with proteinuria and time to ESRD.

255 tistically significant in predicting time to ESRD.

256 ion may retard the progression of CKD toward ESRD.

257 common primary glomerular disease underlying ESRD in the United States and is increasing in incidence

258 The primary outcome was ESRD or 50% reduction in eGFR.

259 idney transplant recipients (1996-2011) with ESRD attributed to one of six GN subtypes or two compara

260 access to transplantation among adults with ESRD.

261 This SNP also associated with ESRD (hazard ratio, 2.0 (95% confidence interval, 1.5 to

262 were no longer significantly associated with ESRD (IRR = 0.92, 95% CI: 0.81, 1.05).

263 lotype was not significantly associated with ESRD (P=0.05 for nondiabetic ESRD, P=0.57 for diabetes-a

264 is known regarding outcomes associated with ESRD opioid prescription.

265 Red meat intake strongly associated with ESRD risk in a dose-dependent manner (hazard ratio for h

266 70, 0.92) were significantly associated with ESRD.

267 ial disparities in survival of children with ESRD is not clear.

268 higher risk of death in obese children with ESRD.

269 ss effacement, and histology consistent with ESRD.

270 her study to ascertain why these donors with ESRD never gained access to the waiting list.

271 rocurement and Transplantation Network, with ESRD ascertainment via Centers for Medicare and Medicaid

272 th between donors and matched nondonors with ESRD.

273 participants with CKD, 100 participants with ESRD, and 25 controls.

274 al benefit for the HIV-infected patient with ESRD, yet this important clinical question remains unans

275 tigen (PSA)-based screening in patients with ESRD affects time to transplantation and transplant outc

276 in is protective or harmful in patients with ESRD and atrial fibrillation.

277 tes, with approximately 50% of patients with ESRD attributed to diabetes in developed countries.

278 9,343), 2001-2010, to identify patients with ESRD due to multiple myeloma treated with RRT (n=12,703)

279 Patients with ESRD exhibited higher odor threshold than the remaining

280 the prevalence of infection in patients with ESRD far exceeded that in the general population.

281 hemodialysis (home HD), offers patients with ESRD greater flexibility and independence.

282 eart failure, and mortality in patients with ESRD on maintenance hemodialysis.

283 Patients with ESRD suffer an exceptionally high cardiovascular risk no

284 ajor source of morbidity among patients with ESRD undergoing maintenance hemodialysis and is a signif

285 Patients with ESRD undergoing peritoneal dialysis develop progressive

286 Older patients with ESRD who receive a kidney transplant (KT) may develop po

287 Among patients with ESRD, cancer risk is affected by kidney dysfunction and

288 that, in prevalent nondiabetic patients with ESRD, PAD associates with low bone turnover and pronounc

289 In patients with ESRD, residual kidney function (RKF) contributes to achi

290 ression on cancer incidence in patients with ESRD, suggesting a need for persistent cancer screening

291 odialysis may benefit selected patients with ESRD.

292 ment that extends the lives of patients with ESRD.

293 R-inducing activity in sera of patients with ESRD.

294 use of cognitive impairment in patients with ESRD.

295 ges in Medicare can affect all patients with ESRD.

296 ore in five out of seven (71%) patients with ESRD.

297 thout (n = 757) a first-degree relative with ESRD.

298 quantified associations of these values with ESRD and mortality over a median of 3.8 years.

299 ion rates for LT recipients with and without ESRD were 2.7 and 1.1 per patient-year at risk, respecti

300 period analysis of 528,108 patients without ESRD before admission, from October of 2012 to September

301 ; importantly, however, the absolute 15-year ESRD incidence in donors remains very low (0.3%).

302 Five-year ESRD-free survival rate was 21% for diffuse mesangial sc

303 Ten-year ESRD-free survival rates were 43%, 94%, and 72% in child